SPM962 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病5

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-000827-15-IT
(EUCTR)
11/05/201315/03/2013LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINELATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE - PARROT Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Rotigotine
Product Name: neurpro
Product Code: SPM962
Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, TricaseNULLNot RecruitingFemale: yes
Male: yes
Italy
2NCT01631825
(ClinicalTrials.gov)
October 200925/6/2012A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease PatientsAn Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopaParkinson's DiseaseDrug: SPM 962Otsuka Pharmaceutical Co., Ltd.NULLCompletedN/AN/AAll321Phase 3Japan
3NCT01628965
(ClinicalTrials.gov)
January 200825/6/2012A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease PatientsAn Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopaParkinson's DiseaseDrug: SPM 962Otsuka Pharmaceutical Co., Ltd.NULLCompletedN/AN/AAll143Phase 2/Phase 3Japan
4NCT01631812
(ClinicalTrials.gov)
December 200625/6/2012A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease PatientsAn Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopaParkinson's DiseaseDrug: SPM 962Otsuka Pharmaceutical Co., Ltd.NULLCompletedN/AN/AAll130Phase 2Japan
5EUCTR2004-002609-66-DE
(EUCTR)
06/12/200422/04/2005A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's diseaseA phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's disease Parkinson's DiseaseProduct Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Schwarz Biosciences GmbHNULLNot RecruitingFemale: yes
Male: yes
60Phase 3Germany;Italy